Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

DISEASE CHARACTERISTICS: * Patients with hematologic malignancies for whom conventional myeloablative allogeneic stem cell transplantation is deemed clinically appropriate and who are eligible for conventional myeloablative allogeneic stem cell transplantation on treatment plans/protocols, including any of the following: * Non-Hodgkin lymphoma or Hodgkin lymphoma (relapsed or refractory disease) * Chronic lymphocytic leukemia (received more than one previous treatment regimen) * Acute myelogenous or lymphoblastic leukemia (AML/ALL) (high-risk disease, in first complete remission \[CR1\] or subsequent remission, or primary refractory disease) * Chronic myelogenous leukemia in tyrosine-kinase resistant chronic phase, accelerated or blast phase, or primary refractory disease * Myelodysplastic syndromes in International Prognostic Scoring System (IPSS) high-intermediate or high-risk groups * Other hematologic disorders for which allogeneic stem cell transplantation is appropriate (e.g., myelofibrosis) * Patients who have relapsed after standard autologous and/or allogeneic bone marrow transplant are eligible * Must be receiving filgrastim (G-CSF)-mobilized related or unrelated donor allogeneic peripheral blood stem cells * Patients receiving hematopoietic stem cells of any other sources such as a marrow graft or umbilical cord blood will not be eligible for this study * Donor must be HLA-genotypically or phenotypically 6 of 6 antigen matched (at the A, B, DR loci…